GlassScriptPhysician profile
Gautam Sharma
NPI 1750345831
$3,654.01
in general payments reported to CMS, 2019-2025
31 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $400 · 2021: $292 · 2022: $558 · 2023: $359 · 2024: $113 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $466.82 | 2019-2024 | Spravato |
| Lundbeck LLC | $404.16 | 2019-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $384.94 | 2019-2023 | Nuedexta |
| Sunovion Pharmaceuticals INC. | $321.29 | 2019-2022 | |
| Allergan, INC. | $255.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.88 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.45 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $204.77 | 2019-2021 | |
| Abbvie INC. | $145.57 | 2021-2023 | Vraylar |
| Corium, LLC | $113.41 | 2022-2023 | Azstarys |
| Alkermes, INC. | $96.50 | 2019-2023 | Lybalvi |
| Shire North American Group INC | $73.75 | 2019 | |
| Avanos Medical | $69.68 | 2025 | Coolief Cooled Radiofrequency |
| Vertical Pharmaceuticals, LLC | $64.39 | 2019 | |
| Tris Pharma INC | $63.96 | 2023 | Dyanavel Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.68 | 2019-2023 | Belsomra |
| Bausch Health US, LLC | $61.28 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $51.93 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $45.29 | 2019-2022 | |
| Adlon Therapeutics L.P. | $43.06 | 2020 | |
| Supernus Pharmaceuticals, INC. | $38.71 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $38.24 | 2021 | |
| Medtronic, INC. | $37.31 | 2022 | |
| Neurocrine Biosciences, INC. | $35.00 | 2019 | |
| Averitas Pharma INC. | $24.57 | 2025 | Qutenza |
| Jazz Pharmaceuticals INC. | $22.49 | 2019 | |
| Boston Scientific Corporation | $22.36 | 2025 | Wavewriter Alpha Prime 16 |
| Axsome Therapeutics, INC. | $20.76 | 2023 | Auvelity |
| Novo Nordisk INC | $19.42 | 2025 | Ozempic, Rybelsus |
| Nalu Medical, INC. | $17.70 | 2025 | Nalu Neurostimulation System |
| Almatica Pharma LLC | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gautam Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.